Summit Therapeutics (SMMT) Enterprise Value (2018 - 2025)
Summit Therapeutics' Enterprise Value history spans 8 years, with the latest figure at -$238.6 million for Q3 2025.
- For Q3 2025, Enterprise Value fell 153.52% year-over-year to -$238.6 million; the TTM value through Sep 2025 reached -$238.6 million, down 153.52%, while the annual FY2024 figure was -$105.2 million, 47.27% down from the prior year.
- Enterprise Value reached -$238.6 million in Q3 2025 per SMMT's latest filing, up from -$298.2 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$28.8 million in Q2 2024 to a low of -$648.6 million in Q4 2022.
- Average Enterprise Value over 5 years is -$178.7 million, with a median of -$105.2 million recorded in 2024.
- Peak YoY movement for Enterprise Value: surged 88.99% in 2023, then tumbled 937.04% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$103.4 million in 2021, then tumbled by 527.28% to -$648.6 million in 2022, then soared by 88.99% to -$71.4 million in 2023, then tumbled by 47.27% to -$105.2 million in 2024, then crashed by 126.79% to -$238.6 million in 2025.
- Per Business Quant, the three most recent readings for SMMT's Enterprise Value are -$238.6 million (Q3 2025), -$298.2 million (Q2 2025), and -$211.8 million (Q1 2025).